Research unlocks insights into lung cancer evolution from electronic medical records
A domain-specific natural language processing (NPL) pipeline showed strong performance in extracting clinically meaningful information from diverse clinical documents of patients with non-small cell lung cancer
RAS inhibition: a game changer in pancreatic cancer?
The hope for innovative and effective RAS-inhibitors is high for this tumour type, but research in this area is challenging
Structured exercise enters ESMO guidelines for colon cancer as recommended treatment
The update reflects survival benefits of post-diagnosis exercise in stage II–III colon cancer as recently reported in the CHALLENGE study
Study supports radiomics in predicting immunotherapy effectiveness in advanced NSCLC
In a real-world study, multimodal artificial intelligence models outperform PD-L1 across key endpoints
Next-generation KRAS G12C inhibitor shows promising activity in advanced colorectal cancer
Manageable safety and encouraging antitumour responses were presented with MK-1084 monotherapy and combination regimens
Study provides prospective validation of an alternative biopsy technique
Data shows that index lesion-focused ipsilateral systematic biopsy is not inferior to standard systematic biopsy
AI model boosts survival prediction accuracy after neoadjuvant chemotherapy in breast cancer
A study compared the performance of different models using routinely collected clinicopathological data from women with HR-positive/HER2-negative breast cancer
Next-generation PRAME-directed TCR T-cell therapy shows early activity in solid tumours
Tumour reduction was observed with IMA203CD8 across different PRAME-expressing cancers in a phase I trial
Retifanlimab prolongs overall survival in advanced squamous cell anal cancer
Benefits were seen across most predefined subgroups investigated in the practice-changing POD1UM-303/InterAACT-2 study
Novel combination shows survival benefits in high-risk gastric/gastro-oesophageal junction cancer
Encouraging data were reported for SHR-1701 added to first-line CAPOX in a post-hoc analysis of patients with high-risk features from a Chinese study